A citation-based method for searching scientific literature

Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins. Diabetes Care 2018
Times Cited: 119



Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 1021




List of shared articles



Times cited


The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Saniya Tandon, Salma Ayis, David Hopkins, Seeromanie Harding, Marietta Stadler. Diabetes Obes Metab 2021
4

Current and future therapies for type 1 diabetes.
Bernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, Matthias von Herrath. Diabetologia 2021
8

Euglycemic diabetic ketoacidosis: A missed diagnosis.
Prashant Nasa, Sandeep Chaudhary, Pavan Kumar Shrivastava, Aanchal Singh. World J Diabetes 2021
1

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
2

The Long-Term Incidence of Hospitalization for Ketoacidosis in Adults with Established T1D-A Prospective Cohort Study.
Merlin Thomas, Valma Harjutsalo, Maija Feodoroff, Carol Forsblom, Daniel Gordin, Per-Henrik Groop. J Clin Endocrinol Metab 2020
3

Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.
C David Mazer, Amel Arnaout, Kim A Connelly, Jeremy D Gilbert, Stephen A Glazer, Subodh Verma, Ronald M Goldenberg. Curr Opin Cardiol 2020
1

Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Bruce A Perkins, Nima Soleymanlou, Julio Rosenstock, Jay S Skyler, Lori M Laffel, Karl-Heinz Liesenfeld, Dietmar Neubacher, Matthew M Riggs, Curtis K Johnston, Rena J Eudy-Byrne,[...]. Diabetes Obes Metab 2020
3

Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease.
Tina Schumann, Jörg König, Christine Henke, Diana M Willmes, Stefan R Bornstein, Jens Jordan, Martin F Fromm, Andreas L Birkenfeld. Pharmacol Rev 2020
28


Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.
Sanjay Kalra, Kimi K Shetty, Vertivel B Nagarajan, Jignesh K Ved. Diabetes Ther 2020
6

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
2

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Erik J M van Bommel, Frank Geurts, Marcel H A Muskiet, Adrian Post, Stephan J L Bakker, A H Jan Danser, Daan J Touw, Miranda van Berkel, Mark H H Kramer, Max Nieuwdorp,[...]. Clin Sci (Lond) 2020
1


Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
5